Mapping Human Clinical Evidence for Chikungunya Vaccines: A Scoping Review of Immunogenicity, Durability, and Safety.

Two chikungunya (CHIKV) vaccines have now been licensed, but the human clinical evidence base remains fragmented across vaccine platforms, populations, follow-up periods, and safety settings, complicating product-specific interpretation of durability and benefit-risk. We conducted a PRISMA-ScR-guided scoping review of human CHIKV vaccine evidence indexed in PubMed, Embase, and Web of Science from January 2000 to June 2026. After screening 890 records, we included 77 sources of evidence and mapped them at both the record level and the candidate/product level. The included evidence clustered around a limited number of vaccine programs, including TSI-GSD-218, VRC-CHKVLP059-00-VP/PXVX0317/Vimkunya, MV-CHIK/V184, VLA1553/IXCHIQ, ChAdOx1 Chik, and mRNA-1388/VAL-181388. Late-stage and post-authorization evidence was concentrated mainly in VLA1553/IXCHIQ and PXVX0317/Vimkunya, whereas viral-vector and mRNA candidates remained largely restricted to early-phase adult studies. Evidence has expanded to adolescents and adults aged ≥65 years for selected products but remains limited or product-specific for children, pregnant individuals, immunocompromised populations, and medically complex older adults. Short-term trial safety data were characterized primarily by mild or moderate local and systemic reactogenicity, while post-authorization safety evidence remains recent and concentrated in licensed products. This scoping review provides a structured evidence map for CHIKV vaccine development and highlights priorities for standardized immunogenicity assessment, longer-term durability data, broader population representation, endemic-region effectiveness studies, and continued post-marketing surveillance.